Skip to main content
. 2020 Apr;8(7):462. doi: 10.21037/atm.2020.03.124

Table 6. Incidence and adjusted hazard ratio of heart failure stratified by cumulative dose of prednisolone, NSAID or ULTs therapy.

Medication exposed N Event Person-year Rate# Adjusted HR (95% CI)
Prednisolone#
   Non-prednisolone 51,455 1,740 366,166 4.75 1.00
   ≤300 mg 60,942 1,919 451,277 4.25 0.77 (0.73, 0.83)***
   >300 mg 38,101 1,630 283,891 5.74 0.61 (0.56, 0.66)***
NSAID#
   Non-NSAID 5,872 174 37,624 4.62 1.00
   ≤28,500 mg 69,409 2,147 493,353 4.35 0.70 (0.60, 0.82)***
   >28,500 mg 75,217 2,968 570,357 5.20 0.45 (0.38, 0.53)***
ULTs
   Non-ULTs 123,162 3,945 885,551 4.45 1.00
   ≤1,200 mg 2,328 146 17,510 8.34 1.93 (1.63, 2.27)***
   >1,200 mg 25,008 1,198 198,272 6.04 1.13 (1.05, 1.20)***

#, the cumulative dose is partitioned in to 2 segments by median; rate#, incidence rate, per 10,000 person-years; adjusted HR, multiple analysis including age, sex, and comorbidities of diabetes, hypertension, hyperlipidemia, chronic kidney disease, stroke, chronic obstructive pulmonary diseases, asthma, alcohol-related illness, and coronary artery disease and medication of prednisolone and NSAID. ***P<0.001. PY, person-years; NSAID, nonsteroid anti-inflammatory drug; ULT, urate lowering theraphy.